alzheimer

One analyst is convinced the biotech stock plunge is 'misguided' (IBB, ALXN, BIIB, VRTX, GILD)

Some investors have been worried about a bubble in biotech stocks, and Wednesday’s sell off seemed to prove those fears.

Biotech stocks fell more than 3%, their biggest one-day drop this year.

But the industry is still one of the best-performing in the market: it’s up 35% over the past 12 months and 9.3% year-to-date, compared to year-to-date gains of 3% for […]

This year's sell off in biotech stocks is starting to look a lot like last year's sell off in biotech stocks (IBB, QQQ …

Biotech investors have been here before.

Stocks are lower on Wednesday and the high-flying biotech sector is leading the way down, with the iShares ETF that tracks the sector falling more than 3%.

And as the sector has weakened over the last several days, this sell off is starting to look at lot like the sell off we saw in the sector […]

Biotech stocks have been getting destroyed, but one analyst says the sell off is 'misguided'

View photo.(Wikimedia Commons)Some investors have been worried about a bubble in biotech stocks, and Wednesday’s sell off seemed to prove those fears.Biotech stocks fell more than 3%, their biggest one-day drop this year.But the industry is still one of the best-performing in the market: it’s up 35% over the past 12 months and 9.3% year-to-date, compared to year-to-date gains of 3% for the […]

Markets Rally On Weaker Dollar, With Dow Breaking Two-Week Losing Streak

(AP Photo/Richard Drew)
Thanks to the removal of just one word in a monetary policy statement and a subsequent weakening in the U.S. dollar, the equity markets have rallied over the last two-and-a-half trading sessions — and the sea of green was abundant in market action on Friday. All three indices opened for trading in positive territory and only climbed […]

Biotech stocks are looking crowded, expert says

The stock has even more upside from where it was trading Friday, around $475 per share, Yaron Werber, senior biotech analyst at Citi Investment Research, told “Power Lunch.” As the Alzheimer’s drug likely will not reach the market for years, it is important to Biogen’s long-term prospects, he said.When looking at valuations, investors need to consider that low interest rates […]